Product
EYP-1901
3 clinical trials
3 indications
Indication
Diabetic RetinopathyIndication
Diabetic Macular EdemaIndication
Age-related Macular DegenerationClinical trial
A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME)Status: Not yet recruiting, Estimated PCD: 2025-01-15
Clinical trial
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMDStatus: Completed, Estimated PCD: 2022-05-11